SLC2A1 and soft tissue sarcoma: A recent study in soft-tissue sarcomas identified a novel subset of CAFs, known as glycolytic CAFs (glyCAFs), which hinder T-cell infiltration through GLUT1-CXCL16 signaling, indicating that targeting glycolysis in CAFs could boost T-cell infiltration and enhance chemotherapy outcomes [17].